BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S, Von Hoff DD. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol 2011;67:503-9. [PMID: 20461382 DOI: 10.1007/s00280-010-1343-8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Kengen J, Deglasse J, Neveu M, Mignion L, Desmet C, Gourgue F, Jonas J, Gallez B, Jordan BF. Biomarkers of tumour redox status in response to modulations of glutathione and thioredoxin antioxidant pathways. Free Radical Research 2018;52:256-66. [DOI: 10.1080/10715762.2018.1427236] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
2 Sebastian S, Zhu YX, Braggio E, Shi CX, Panchabhai SC, Van Wier SA, Ahmann GJ, Chesi M, Bergsagel PL, Stewart AK, Fonseca R. Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity. Blood 2017;129:991-1007. [PMID: 28028022 DOI: 10.1182/blood-2016-09-738872] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
3 Xu Y, Shi X, Wu L. t BuOK-triggered bond formation reactions. RSC Adv 2019;9:24025-9. [DOI: 10.1039/c9ra04242c] [Cited by in Crossref: 16] [Article Influence: 5.3] [Reference Citation Analysis]
4 Li S, Wang H, Liu H, Jing F, Fu X, Li C, Shi Y, Chen B. Synthesis and biological evaluation of novel disulfides incorporating 1,3,4-thiadiazole scaffold as promising antitumor agents. Med Chem Res 2019;28:1502-8. [DOI: 10.1007/s00044-019-02389-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
5 Rossetto O, Pirazzini M, Lista F, Montecucco C. The role of the single interchains disulfide bond in tetanus and botulinum neurotoxins and the development of antitetanus and antibotulism drugs. Cell Microbiol 2019;21:e13037. [PMID: 31050145 DOI: 10.1111/cmi.13037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Lu Y, Song G, He B, Zhang H, Wang X, Zhou D, Dai W, Zhang Q. Strengthened Tumor Photodynamic Therapy Based on a Visible Nanoscale Covalent Organic Polymer Engineered by Microwave Assisted Synthesis. Adv Funct Mater 2020;30:2004834. [DOI: 10.1002/adfm.202004834] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Ehrenfeld V, Fulda S. Thioredoxin inhibitor PX-12 induces mitochondria-mediated apoptosis in acute lymphoblastic leukemia cells. Biol Chem 2020;401:273-83. [PMID: 31352431 DOI: 10.1515/hsz-2019-0160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Hua J, Shi S, Liang D, Liang C, Meng Q, Zhang B, Ni Q, Xu J, Yu X. Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining? Onco Targets Ther 2018;11:4591-608. [PMID: 30122951 DOI: 10.2147/OTT.S166405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
9 Liu Y, Li J, Liu X, Li Z, Men Y, Sun Y, Chen B. Design, synthesis, and screening for the antiproliferative activity of new 1,3,4-thiadiazole scaffold linked to substituted phenacyl derivatives and disulfides. Journal of Sulfur Chemistry. [DOI: 10.1080/17415993.2022.2071588] [Reference Citation Analysis]
10 Metcalfe C, Ramasubramoni A, Pula G, Harper MT, Mundell SJ, Coxon CH. Thioredoxin Inhibitors Attenuate Platelet Function and Thrombus Formation. PLoS One 2016;11:e0163006. [PMID: 27716777 DOI: 10.1371/journal.pone.0163006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
11 Lu Y, Zhao X, Luo G, Shen G, Li K, Ren G, Pan Y, Wang X, Fan D. Thioredoxin-like protein 2b facilitates colon cancer cell proliferation and inhibits apoptosis via NF-κB pathway. Cancer Letters 2015;363:119-26. [DOI: 10.1016/j.canlet.2014.12.048] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
12 Cao MQ, You AB, Cui W, Zhang S, Guo ZG, Chen L, Zhu XD, Zhang W, Zhu XL, Guo H, Deng DJ, Sun HC, Zhang T. Cross talk between oxidative stress and hypoxia via thioredoxin and HIF-2α drives metastasis of hepatocellular carcinoma. FASEB J 2020;34:5892-905. [PMID: 32157720 DOI: 10.1096/fj.202000082R] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 DiRaimondo TR, Plugis NM, Jin X, Khosla C. Selective inhibition of extracellular thioredoxin by asymmetric disulfides. J Med Chem 2013;56:1301-10. [PMID: 23327656 DOI: 10.1021/jm301775s] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
14 Ramanathan RK, Stephenson JJ, Weiss GJ, Pestano LA, Lowe A, Hiscox A, Leos RA, Martin JC, Kirkpatrick L, Richards DA. A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. Invest New Drugs 2012;30:1591-6. [PMID: 21863237 DOI: 10.1007/s10637-011-9739-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
15 Sulic AM, Kurppa K, Rauhavirta T, Kaukinen K, Lindfors K. Transglutaminase as a therapeutic target for celiac disease. Expert Opin Ther Targets 2015;19:335-48. [PMID: 25410283 DOI: 10.1517/14728222.2014.985207] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
16 Ghareeb H, Metanis N. The Thioredoxin System: A Promising Target for Cancer Drug Development. Chemistry 2020;26:10175-84. [PMID: 32097513 DOI: 10.1002/chem.201905792] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
17 Jones DT, Harris AL. Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions. Expert Opin Ther Targets 2012;16:463-80. [PMID: 22512262 DOI: 10.1517/14728222.2012.674516] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
18 Pirazzini M, Azarnia Tehran D, Zanetti G, Lista F, Binz T, Shone CC, Rossetto O, Montecucco C. The thioredoxin reductase--Thioredoxin redox system cleaves the interchain disulphide bond of botulinum neurotoxins on the cytosolic surface of synaptic vesicles. Toxicon 2015;107:32-6. [PMID: 26130523 DOI: 10.1016/j.toxicon.2015.06.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
19 Samaranayake GJ, Troccoli CI, Huynh M, Lyles RDZ, Kage K, Win A, Lakshmanan V, Kwon D, Ban Y, Chen SX, Zarco ER, Jorda M, Burnstein KL, Rai P. Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer. Nat Commun 2017;8:1204. [PMID: 29089489 DOI: 10.1038/s41467-017-01269-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
20 Mao Z, Yang X, Mizutani S, Huang Y, Zhang Z, Shinmori H, Gao K, Yao J. Hydrogen Sulfide Mediates Tumor Cell Resistance to Thioredoxin Inhibitor. Front Oncol 2020;10:252. [PMID: 32219063 DOI: 10.3389/fonc.2020.00252] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 May HC, Yu JJ, Guentzel MN, Chambers JP, Cap AP, Arulanandam BP. Repurposing Auranofin, Ebselen, and PX-12 as Antimicrobial Agents Targeting the Thioredoxin System. Front Microbiol 2018;9:336. [PMID: 29556223 DOI: 10.3389/fmicb.2018.00336] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
22 Narayanan D, Ma S, Özcelik D. Targeting the Redox Landscape in Cancer Therapy. Cancers (Basel) 2020;12:E1706. [PMID: 32605023 DOI: 10.3390/cancers12071706] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
23 Monteiro HP, Ogata FT, Stern A. Thioredoxin promotes survival signaling events under nitrosative/oxidative stress associated with cancer development. Biomed J 2017;40:189-99. [PMID: 28918907 DOI: 10.1016/j.bj.2017.06.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
24 Cabello CM, Lamore SD, Bair WB 3rd, Davis AL, Azimian SM, Wondrak GT. DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma. Free Radic Res 2011;45:276-92. [PMID: 21034357 DOI: 10.3109/10715762.2010.526766] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
25 Sun J, Russell CC, Scarlett CJ, McCluskey A. Small molecule inhibitors in pancreatic cancer. RSC Med Chem 2020;11:164-83. [PMID: 33479626 DOI: 10.1039/c9md00447e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
26 Zhang W, Zhu Y, Yu H, Liu X, Jiao B, Lu X. Libertellenone H, a Natural Pimarane Diterpenoid, Inhibits Thioredoxin System and Induces ROS-Mediated Apoptosis in Human Pancreatic Cancer Cells. Molecules 2021;26:E315. [PMID: 33435380 DOI: 10.3390/molecules26020315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Raninga PV, Di Trapani G, Vuckovic S, Bhatia M, Tonissen KF. Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma. Oncotarget 2015;6:15410-24. [PMID: 25945832 DOI: 10.18632/oncotarget.3795] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 9.8] [Reference Citation Analysis]
28 Hsiao HT, Lin YC, Wang JC, Tsai YC, Liu YC. Hypoxia inducible factor-1α inhibition produced anti-allodynia effect and suppressed inflammatory cytokine production in early stage of mouse complex regional pain syndrome model. Clin Exp Pharmacol Physiol 2016;43:355-9. [PMID: 26711019 DOI: 10.1111/1440-1681.12536] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
29 Baker AF, Adab KN, Raghunand N, Chow H, Stratton SP, Squire SW, Boice M, Pestano LA, Kirkpatrick DL, Dragovich T. A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers. Invest New Drugs 2013;31:631-41. [PMID: 22711542 DOI: 10.1007/s10637-012-9846-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
30 Ren S, Luo N, Liu K, Liu J. Synthesis of unsymmetrical disulfides via the cross-dehydrogenation of thiols. Journal of Chemical Research 2021;45:365-73. [DOI: 10.1177/1747519820942872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Aprile G, Negri FV, Giuliani F, De Carlo E, Melisi D, Simionato F, Silvestris N, Brunetti O, Leone F, Marino D, Santini D, Dell'Aquila E, Zeppola T, Puzzoni M, Scartozzi M. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? Crit Rev Oncol Hematol 2017;115:1-12. [PMID: 28602164 DOI: 10.1016/j.critrevonc.2017.03.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
32 Zhang Y, Zhou J, Ye Q, Zeng K, Pan J, Chen L, Wang Y, Yang B, He Q, Gao J, Zeng S, Yu L. 6-Dithio-2'-deoxyguanosine analogs induce reactive oxygen species-mediated tumor cell apoptosis via bi-targeting thioredoxin 1 and telomerase. Toxicol Appl Pharmacol 2020;401:115079. [PMID: 32497534 DOI: 10.1016/j.taap.2020.115079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Li B, Li B, Zhang R, Zhao J, Wang X, Liu Y, Shi Y, Liu J, Chen B. Synthesis and antiproliferative evaluation of novel 1,2,4-triazole derivatives incorporating benzisoselenazolone scaffold. Bioorganic & Medicinal Chemistry Letters 2016;26:1279-81. [DOI: 10.1016/j.bmcl.2016.01.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
34 Hu J, Wang F, Liu F, Sun W, Jiang Q, Liu Y, Zhao Y, Liu X. Effective nanotherapeutic approach for metastatic breast cancer treatment by supplemental oxygenation and imaging-guided phototherapy. Nano Res 2020;13:1111-21. [DOI: 10.1007/s12274-020-2753-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Zhou Y, Tu X, Li Z, Zhou L, Zeng Q. Catalyst-free Synthesis of 2-( tert -Butyldisulfanyl) Heterocycles from tert -Butanesulfinamide and Mercapto-substituted Imidazoles, Tetrazole, Pyrimidine and Pyridine. Organic Preparations and Procedures International 2016;48:413-20. [DOI: 10.1080/00304948.2016.1206440] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
36 Durand N, Storz P. Targeting reactive oxygen species in development and progression of pancreatic cancer. Expert Rev Anticancer Ther 2017;17:19-31. [PMID: 27841037 DOI: 10.1080/14737140.2017.1261017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
37 Zanetti G, Azarnia Tehran D, Pirazzini M, Binz T, Shone CC, Fillo S, Lista F, Rossetto O, Montecucco C. Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism. Biochem Pharmacol 2015;98:522-30. [PMID: 26449594 DOI: 10.1016/j.bcp.2015.09.023] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
38 Nagrial AM, Chin VT, Sjoquist KM, Pajic M, Horvath LG, Biankin AV, Yip D. Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Crit Rev Oncol Hematol. 2015;96:483-497. [PMID: 26481952 DOI: 10.1016/j.critrevonc.2015.07.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
39 Shang W, Xie Z, Lu F, Fang D, Tang T, Bi R, Chen L, Jiang L. Increased Thioredoxin-1 Expression Promotes Cancer Progression and Predicts Poor Prognosis in Patients with Gastric Cancer. Oxid Med Cell Longev 2019;2019:9291683. [PMID: 30911354 DOI: 10.1155/2019/9291683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
40 Ye Y, Hu Q, Chen H, Liang K, Yuan Y, Xiang Y, Ruan H, Zhang Z, Song A, Zhang H, Liu L, Diao L, Lou Y, Zhou B, Wang L, Zhou S, Gao J, Jonasch E, Lin SH, Xia Y, Lin C, Yang L, Mills GB, Liang H, Han L. Characterization of Hypoxia-associated Molecular Features to Aid Hypoxia-Targeted Therapy. Nat Metab. 2019;1:431-444. [PMID: 31984309 DOI: 10.1038/s42255-019-0045-8] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 19.3] [Reference Citation Analysis]
41 Wu W, Wong Y, Tan Z, Wu J. Photo-induced thiol coupling and C–H activation using nanocrystalline lead-halide perovskite catalysts. Catal Sci Technol 2018;8:4257-63. [DOI: 10.1039/c8cy01240g] [Cited by in Crossref: 54] [Cited by in F6Publishing: 1] [Article Influence: 13.5] [Reference Citation Analysis]
42 Hayes AJ, Skouras C, Haugk B, Charnley RM. Keap1-Nrf2 signalling in pancreatic cancer. Int J Biochem Cell Biol 2015;65:288-99. [PMID: 26117456 DOI: 10.1016/j.biocel.2015.06.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
43 Xie W, Ma W, Liu P, Zhou F. Overview of thioredoxin system and targeted therapies for acute leukemia. Mitochondrion 2019;47:38-46. [DOI: 10.1016/j.mito.2019.04.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
44 Nagano M, Hatakeyama K, Kai M, Nakamura H, Yodoi J, Asada Y, Chijiiwa K. Nuclear expression of thioredoxin-1 in the invasion front is associated with outcome in patients with gallbladder carcinoma. HPB (Oxford) 2012;14:573-82. [PMID: 22882193 DOI: 10.1111/j.1477-2574.2012.00482.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
45 He J, Li D, Xiong K, Ge Y, Jin H, Zhang G, Hong M, Tian Y, Yin J, Zeng H. Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy. Bioorganic & Medicinal Chemistry 2012;20:3816-27. [DOI: 10.1016/j.bmc.2012.04.033] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
46 Zhang J, Duan D, Song ZL, Liu T, Hou Y, Fang J. Small molecules regulating reactive oxygen species homeostasis for cancer therapy. Med Res Rev 2021;41:342-94. [PMID: 32981100 DOI: 10.1002/med.21734] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
47 Yuan J, Liu C, Lei A. Oxidative cross S–H/S–H coupling: selective synthesis of unsymmetrical aryl tert-alkyl disulfanes. Org Chem Front 2015;2:677-80. [DOI: 10.1039/c5qo00027k] [Cited by in Crossref: 37] [Article Influence: 5.3] [Reference Citation Analysis]
48 Zhang B, Zhang J, Peng S, Liu R, Li X, Hou Y, Han X, Fang J. Thioredoxin reductase inhibitors: a patent review. Expert Opinion on Therapeutic Patents 2017;27:547-56. [DOI: 10.1080/13543776.2017.1272576] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
49 Hu Y, Liu J, Huang H. Recent agents targeting HIF-1α for cancer therapy. J Cell Biochem. 2013;114:498-509. [PMID: 22961911 DOI: 10.1002/jcb.24390] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 9.2] [Reference Citation Analysis]
50 Wang Y, Qi H, Liu Y, Duan C, Liu X, Xia T, Chen D, Piao HL, Liu HX. The double-edged roles of ROS in cancer prevention and therapy. Theranostics 2021;11:4839-57. [PMID: 33754031 DOI: 10.7150/thno.56747] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
51 Pirazzini M, Azarnia Tehran D, Zanetti G, Megighian A, Scorzeto M, Fillo S, Shone CC, Binz T, Rossetto O, Lista F, Montecucco C. Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. Cell Rep 2014;8:1870-8. [PMID: 25220457 DOI: 10.1016/j.celrep.2014.08.017] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 8.0] [Reference Citation Analysis]
52 Cardoso AA, Jiang Y, Luo M, Reed AM, Shahda S, He Y, Maitra A, Kelley MR, Fishel ML. APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival. PLoS One 2012;7:e47462. [PMID: 23094050 DOI: 10.1371/journal.pone.0047462] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
53 Philot EA, da Mata Lopes D, de Souza AT, Braz AS, Nantes IL, Rodrigues T, Perahia D, Miteva MA, Scott LP. Binding of phenothiazines into allosteric hydrophobic pocket of human thioredoxin 1. Eur Biophys J 2016;45:279-86. [PMID: 26820562 DOI: 10.1007/s00249-016-1113-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 An N, Kang Y. Thioredoxin and hematologic malignancies. Adv Cancer Res 2014;122:245-79. [PMID: 24974184 DOI: 10.1016/B978-0-12-420117-0.00007-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
55 Qiao S, Lamore SD, Cabello CM, Lesson JL, Muñoz-Rodriguez JL, Wondrak GT. Thiostrepton is an inducer of oxidative and proteotoxic stress that impairs viability of human melanoma cells but not primary melanocytes. Biochem Pharmacol 2012;83:1229-40. [PMID: 22321511 DOI: 10.1016/j.bcp.2012.01.027] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
56 Reynoso E, Liu H, Li L, Yuan AL, Chen S, Wang Z. Thioredoxin-1 actively maintains the pseudokinase MLKL in a reduced state to suppress disulfide bond-dependent MLKL polymer formation and necroptosis. J Biol Chem 2017;292:17514-24. [PMID: 28878015 DOI: 10.1074/jbc.M117.799353] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
57 Digiacomo JW, Gilkes DM. Therapeutic Strategies to Block the Hypoxic Response. In: Gilkes DM, editor. Hypoxia and Cancer Metastasis. Cham: Springer International Publishing; 2019. pp. 141-57. [DOI: 10.1007/978-3-030-12734-3_10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
58 Kekulandara DN, Nagi S, Seo H, Chow CS, Ahn YH. Redox-Inactive Peptide Disrupting Trx1-Ask1 Interaction for Selective Activation of Stress Signaling. Biochemistry 2018;57:772-80. [PMID: 29261301 DOI: 10.1021/acs.biochem.7b01083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
59 Wigerup C, Påhlman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther 2016;164:152-69. [PMID: 27139518 DOI: 10.1016/j.pharmthera.2016.04.009] [Cited by in Crossref: 291] [Cited by in F6Publishing: 282] [Article Influence: 48.5] [Reference Citation Analysis]
60 Leal SM Jr, Vareechon C, Cowden S, Cobb BA, Latgé JP, Momany M, Pearlman E. Fungal antioxidant pathways promote survival against neutrophils during infection. J Clin Invest 2012;122:2482-98. [PMID: 22706306 DOI: 10.1172/JCI63239] [Cited by in Crossref: 73] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
61 Yaakoub H, Staerck C, Mina S, Godon C, Fleury M, Bouchara JP, Calenda A. Repurposing of auranofin and honokiol as antifungals against Scedosporium species and the related fungus Lomentospora prolificans. Virulence 2021;12:1076-90. [PMID: 33825667 DOI: 10.1080/21505594.2021.1909266] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Jiang H, Wang H, De Ridder M. Targeting antioxidant enzymes as a radiosensitizing strategy. Cancer Lett 2018;438:154-64. [PMID: 30223069 DOI: 10.1016/j.canlet.2018.09.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
63 Telarovic I, Wenger RH, Pruschy M. Interfering with Tumor Hypoxia for Radiotherapy Optimization. J Exp Clin Cancer Res 2021;40:197. [PMID: 34154610 DOI: 10.1186/s13046-021-02000-x] [Reference Citation Analysis]
64 Wei X, Zhong M, Wang S, Li L, Song ZL, Zhang J, Xu J, Fang J. Synthesis and biological evaluation of disulfides as anticancer agents with thioredoxin inhibition. Bioorg Chem 2021;110:104814. [PMID: 33756234 DOI: 10.1016/j.bioorg.2021.104814] [Reference Citation Analysis]
65 Mahmood DF, Abderrazak A, El Hadri K, Simmet T, Rouis M. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal 2013;19:1266-303. [PMID: 23244617 DOI: 10.1089/ars.2012.4757] [Cited by in Crossref: 173] [Cited by in F6Publishing: 164] [Article Influence: 19.2] [Reference Citation Analysis]
66 Schultz MA, Diaz AM, Smite S, Lay AR, DeCant B, McKinney R, Mascarinas WE, Xia Y, Neumann C, Bentrem D, Dawson DW, Grippo PJ. Thioredoxin system-mediated regulation of mutant Kras associated pancreatic neoplasia and cancer. Oncotarget 2017;8:92667-81. [PMID: 29190947 DOI: 10.18632/oncotarget.21539] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
67 Chin V, Nagrial A, Sjoquist K, O'Connor CA, Chantrill L, Biankin AV, Scholten RJ, Yip D. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev 2018;3:CD011044. [PMID: 29557103 DOI: 10.1002/14651858.CD011044.pub2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
68 Zhang J, Li X, Han X, Liu R, Fang J. Targeting the Thioredoxin System for Cancer Therapy. Trends Pharmacol Sci 2017;38:794-808. [PMID: 28648527 DOI: 10.1016/j.tips.2017.06.001] [Cited by in Crossref: 146] [Cited by in F6Publishing: 149] [Article Influence: 29.2] [Reference Citation Analysis]
69 Kirkpatrick DL, Powis G. Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling. Antioxid Redox Signal 2017;26:262-73. [PMID: 26983373 DOI: 10.1089/ars.2016.6633] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]